Xiaomeng Yue1, Jeff Jianfei Guo2, Patricia R Wigle3. 1. PhD Student, James L. Winkle College of Pharmacy, University of Cincinnati Academic Health Center, OH. 2. Professor of Pharmacoeconomics & Pharmacoepidemiology, James L. Winkle College of Pharmacy, University of Cincinnati Academic Health Center, OH. 3. Professor, Pharmacy Practice, James L. Winkle College of Pharmacy, University of Cincinnati Academic Health Center, OH.
Abstract
BACKGROUND: Smoking remains the single largest preventable cause of death and disease. Smoking-cessation medications provide patients a multitude of benefits and can prevent certain diseases, including some cancers. Because of the limited amount of studies on smoking-cessation medications, we wanted to find general trends about the use of these medications. OBJECTIVE: To examine trends in the utilization, pharmacy reimbursement, and prices of smoking-cessation medications and nicotine replacement therapy in the US Medicaid-covered population. METHODS: Using national summary files for outpatient drug utilization and expenditure, we extracted data on smoking-cessation medications from the Centers for Medicare & Medicaid Services in the 25 years from January 1991 through June 2015. We conducted a retrospective drug utilization study to examine the annual (or quarterly) trends of the number of prescriptions, reimbursement expenditures, and the prices of smoking-cessation medications. The study drugs included varenicline (Chantix), bupropion (Zyban), and nicotine. We calculated per-prescription pharmacy reimbursement, which was used as a proxy for drug price, as the total quarterly expenditure for the drug, divided by the total number of prescriptions. All expenditures were inflated to 2015 US dollars using the medical services component of the Consumer Price Index. RESULTS: The total number of prescriptions for smoking-cessation medications increased rapidly from 46,396 in 1991 to 942,562 in 2014, an increase of more than 1931%. During the same period, the total pharmacy reimbursement for smoking-cessation medications in Medicaid increased by 3562%, from approximately $2.8 million in 1991 to approximately $101 million in 2014. The use of the nonnicotine prescription drugs varenicline and bupropion also increased rapidly, with a high cost expenditure. The price per nonnicotine prescription drug increased over time, ranging from approximately $169 for bupropion to approximately $251 for varenicline in 2015. CONCLUSIONS: The substantial increase in nonnicotine prescription drugs and nicotine replacement therapy between 2007 and 2015 may be attributed to smoking-cessation participants nationwide. Cost-containment policies might have inadvertently prevented Medicaid-covered smokers from obtaining appropriate pharmacotherapy.
BACKGROUND: Smoking remains the single largest preventable cause of death and disease. Smoking-cessation medications provide patients a multitude of benefits and can prevent certain diseases, including some cancers. Because of the limited amount of studies on smoking-cessation medications, we wanted to find general trends about the use of these medications. OBJECTIVE: To examine trends in the utilization, pharmacy reimbursement, and prices of smoking-cessation medications and nicotine replacement therapy in the US Medicaid-covered population. METHODS: Using national summary files for outpatient drug utilization and expenditure, we extracted data on smoking-cessation medications from the Centers for Medicare & Medicaid Services in the 25 years from January 1991 through June 2015. We conducted a retrospective drug utilization study to examine the annual (or quarterly) trends of the number of prescriptions, reimbursement expenditures, and the prices of smoking-cessation medications. The study drugs included varenicline (Chantix), bupropion (Zyban), and nicotine. We calculated per-prescription pharmacy reimbursement, which was used as a proxy for drug price, as the total quarterly expenditure for the drug, divided by the total number of prescriptions. All expenditures were inflated to 2015 US dollars using the medical services component of the Consumer Price Index. RESULTS: The total number of prescriptions for smoking-cessation medications increased rapidly from 46,396 in 1991 to 942,562 in 2014, an increase of more than 1931%. During the same period, the total pharmacy reimbursement for smoking-cessation medications in Medicaid increased by 3562%, from approximately $2.8 million in 1991 to approximately $101 million in 2014. The use of the nonnicotine prescription drugs varenicline and bupropion also increased rapidly, with a high cost expenditure. The price per nonnicotine prescription drug increased over time, ranging from approximately $169 for bupropion to approximately $251 for varenicline in 2015. CONCLUSIONS: The substantial increase in nonnicotine prescription drugs and nicotine replacement therapy between 2007 and 2015 may be attributed to smoking-cessation participants nationwide. Cost-containment policies might have inadvertently prevented Medicaid-covered smokers from obtaining appropriate pharmacotherapy.
Authors: Steffani R Bailey; John D Heintzman; Miguel Marino; R Lorie Jacob; Jon E Puro; Jennifer E DeVoe; Tim E Burdick; Brian L Hazlehurst; Deborah J Cohen; Stephen P Fortmann Journal: Am J Prev Med Date: 2017-03-29 Impact factor: 5.043
Authors: Michael V Maciosek; Amy B LaFrance; Steven P Dehmer; Dana A McGree; Zack Xu; Thomas J Flottemesch; Leif I Solberg Journal: Ann Fam Med Date: 2017-01-06 Impact factor: 5.166
Authors: Anne DiGiulio; Meredith Haddix; Zach Jump; Stephen Babb; Anna Schecter; Kisha-Ann S Williams; Kat Asman; Brian S Armour Journal: MMWR Morb Mortal Wkly Rep Date: 2016-12-09 Impact factor: 17.586
Authors: Jennifer Kahende; Ann Malarcher; Lucinda England; Lei Zhang; Paul Mowery; Xin Xu; Varadan Sevilimedu; Italia Rolle Journal: PLoS One Date: 2017-02-16 Impact factor: 3.240
Authors: Sundar S Shrestha; Xin Xu; Xu Wang; Stephen D Babb; Brian S Armour; Brian A King; Katrina F Trivers Journal: Public Health Rep Date: 2021-02-18 Impact factor: 2.792